Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel.
Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on Doctor and patients’ perspectives on myeloma CAR-T on Tuesday, 14 February 2023 from 17:30 – 19:00 CET.
Continue reading
Influenza (i.e. “flu”) and pneumococcal vaccinations positively impact the outcomes of myeloma patients. This is the central conclusion in the article Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma (MM) Patients: Influenza and Pneumococcal Vaccination in MM, published in Clinical Lymphoma, Myeloma and Leukaemia.
Myeloma Patients Europe’s (MPE) 2022 Year in Review is snapshot of the major accomplishments from the past year.
Myeloma Patients Europe (MPE) is attending the 64th American Society of Hematology (ASH) Annual Meeting, the biggest haematology congress, held from 9 to 13 December in New Orleans (United States). MPE has interviewed haematology experts to summarise the latest updates on myeloma and AL amyloidosis:
NEW ORLEANS. New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition focuses on talquetamab in patients with Relapsed/Refractory myeloma. In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy for myeloma, saw a significant reduction in cancer burden within a few months. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new hope for patients with hard-to-treat myeloma. Continue reading
Myeloma Patients Europe (MPE) has today launched a first-of-its-kind advocacy report on Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE).
Starting in December 2022, the HORIZON-funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and Reimbursement models to Appraise innovative health technologies) will address the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. Affording newly approved innovative health technologies (IHTs) is challenging in many health systems.
According to a study published in Blood Advances, caregivers of patients undergoing a stem cell transplant cope with high caregiver burden, psychological distress, and worse quality of life.
- Position: Finance Officer
- Type: Part-Time ( 3 days/per week)
- Location: Remote. Must be based in Germany.
- Department: Finance and Operations